David M. Swoboda, MD

Panelists discuss how Janus kinase (JAK) inhibitors, including ruxolitinib, fedratinib, pacritinib, and momelotinib, as well as investigational agents like pelabresib and navitoclax, target the dysregulated JAK-STAT pathway to manage symptoms and potentially modify disease progression in myelofibrosis.

Panelists discuss how myelofibrosis management involves a combination of medications, supportive care, and potentially stem cell transplantation to alleviate symptoms, control disease progression, and improve quality of life.